Octreotide
FDA approved · RxSomatostatin analogue peptide
Also known as: Sandostatin, Mycapssa, Bynfezia, Bynfezia Pen, Octreotide Acetate, Octreotida, Octreotidum, SMS-201-995, SMS995, SMS-995
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 327 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Octreotide is a synthetic peptide that mimics somatostatin, a natural hormone that suppresses the release of several other hormones. It binds mainly to somatostatin receptors (especially subtype 2), reducing secretion of growth hormone, insulin-like growth factor 1, and various gut hormones. It is sold under names including Sandostatin, Mycapssa, and Bynfezia.
What the evidence shows
Octreotide is FDA-approved for acromegaly and for symptom control in certain neuroendocrine tumors, such as severe diarrhea and flushing from carcinoid tumors and watery diarrhea from VIP-secreting tumors. It has a large human evidence base with over 300 registered trials and thousands of published papers, though uses outside its approved indications are less firmly established.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Biomarker Study of Pancreatic Neuroendocrine Tumours
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine Tumors.
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress.
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Sources
- PubChem compound record (CID 448601)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.